Stock ALZH ALZHEON, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Alzheon, Inc. Stock

Equities

ALZH

US00168L1017

Biotechnology & Medical Research

Chart Alzheon, Inc.

Dynamic Chart

Latest news about Alzheon, Inc.

Alzheon, Inc. announced a financing transaction CI
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer CI
Alzheon, Inc. to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer's Disease Conference CI
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer?s Disease Day, and BIO Investor Forum CI
Alzheon Reports Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 in Patients with Early Alzheimer's Disease CI
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet CI
Alzheon, Inc. to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study At American Academy of Neurology Conference in Boston CI
Alzheon, IncAnnounces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease CI
Alzheon, Inc. announced that it expects to receive $50.004201 million in funding CI
Alzheon, Inc. Reports Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral Alz-801 (Valiltramiprosate) in Patients with Early Alzheimer’S Disease CI
Alzheon, Inc Appoints Glenn Pauly as Head of Commercial CI
Alzheon, Inc. to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ -801 (Valiltramiprosate) Oral Tablet At 2022 Alzheimer’S Association International Conference CI
Alzheon, Inc. announced that it has received $50.000004 million in funding CI
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease At AD/PD and NDDS Scientific Conferences CI
Alzheon Reports Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease CI
More news

Managers and Directors - Alzheon, Inc.

Managers TitleAgeSince
Martin Tolar FOU
 Founder 59 13-05-31
Kenneth A. Mace DFI
 Director of Finance/CFO 52 15-08-31
Adem Albayrak COO
 Chief Operating Officer - 21-09-12
Members of the board TitleAgeSince
Jordan Heller BRD
 Director/Board Member 62 20-01-07
Neil William Flanzraich CHM
 Chairman 80 18-08-05
Martin Tolar FOU
 Founder 59 13-05-31
More insiders

Company Profile

Alzheon Inc is a United States-based clinical-stage biopharmaceutical company. The company is developing medicines for patients suffering from alzheimer's disease and other neurological and psychiatric disorders. The Company is focused on brain health, memory and aging and develops treatments for alzheimer's disease and other neurodegenerative disorders.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.84B
LONZA GROUP AG Stock Lonza Group AG
+46.96% 41.25B
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.68B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.18B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALZH Stock